Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC010 Combinations in Patients With Advanced Solid Tumors
NCT07477743Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC010 in gastrointestinal cancer and solid tumor (3 arms). Primary endpoint: Dose-limiting toxicities at 21 days. Started Mar 2026; status: recruiting.
02
Drugs
HC010
03
Conditions
gastrointestinal cancersolid tumor
Beyond the preview
Go deeper on NCT07477743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477743.